Product Name

Luliconazole

CAS Number

187164-19-8

LGM Pharma is an API distributor. LGM Pharma can supply CGMP and/or DMF products, subject to availability and manufacturer requirements. LGM Pharma does not sell or supply APIs or finished dosage products to individual patients, doctors, pharmacies, or any pharmaceutical companies.

Questions? Call our customer API support number 1-(800)-881-8210

Product Name:
Luliconazole
CAS Number:
187164-19-8
Indication:
Luliconazole is indicated in adults aged 18 years and older for the topical treatment of fungal infections caused by Trichophyton rubrum and Epidermophyton floccosum, specifically tinea pedis, cruris, and corporis.
Mode of Action:

The exact mechanism of action for luliconazole’s anti-fungal activity is still not known, but luliconazole is thought to inhibit the enzyme lanosterol demethylase. Lanosterol demethylase is needed for the synthesis of ergosterol, which is a major component of the fungus cell membranes.

Pharmacodynamics:

Luliconazole kills the organisms Trichophyton rubrum and Epidermophyton floccosum, most likely by altering their fungal cell membranes.

Metabolism:

The metabolism of luliconazole has yet to be determined.

Toxicity:

In clinical trials, no serious toxicity was reported, only local irritation (mild contact dermatitis and cellulitis) at the site of application was found.

IUPAC:
2-[(2E)-4-(2, 4-dichlorophenyl)-1, 3-dithiolan-2-ylidene]-2-(1H-imidazol-1-yl)acetonitrile
ATC:
D01AC18
PubChem:
9863407
DrugBank:
DB08933
Formula:
C14-H9-Cl2-N3-S2
Molecular Mass:
354.2841
Synonyms:
(-)-(E)-((4R)-4-(2,4-Dichlorophenyl)-1,3-dithiolan-2-ylidene)(1H-imidazol-1-yl)acetonitrile, Luliconazole, Luzu, NND 502, NND-502, NND502, PR-2699, UNII-RE91AN4S8G
SMILES:
c1cc(c(cc1Cl)Cl)[C@@H]2CS/C(=C(/C#N)3ccnc3)/S2
InChi:
1S/C14H9Cl2N3S2/c15-9-1-2-10(11(16)5-9)13-7-20-14(21-13)12(6-17)19-4-3-18-8-19/h1-5,8,13H,7H2/b14-12+/t13-/m0/s1
General Reference:
General Reference:

 

  1. Niwano Y, Kuzuhara N, Kodama H, Yoshida M, Miyazaki T, Yamaguchi H: In vitro and in vivo antidermatophyte activities of NND-502, a novel optically active imidazole antimycotic agent. Antimicrob Agents Chemother. 1998 Apr;42(4):967-70. Pubmed
  2. Uchida K, Nishiyama Y, Yamaguchi H: In vitro antifungal activity of luliconazole (NND-502), a novel imidazole antifungal agent. J Infect Chemother. 2004 Aug;10(4):216-9. Pubmed
  3. Lexicomp.
  4. FDA label.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

LGM currently offers Monoclonal Antibodies (mAbs) for non-GMP/R&D use. Please inquire about Monoclonal Antibodies produced under GMP conditions.

Questions? Call our customer API support number 1-(800)-881-8210. 

Ask us about this product

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants
  • Technical packages as well as access to filed DMF, ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any submission type based on specific customer requirements

Find an API Product

SEARCH
Generic filters